Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 34.00 | |
5 mg | In stock | $ 55.00 | |
10 mg | In stock | $ 98.00 | |
25 mg | In stock | $ 197.00 | |
50 mg | In stock | $ 360.00 | |
100 mg | In stock | $ 587.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 61.00 |
Description | BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2. |
Targets&IC50 | HIV-I integrase:15 nM |
In vitro | BMS-707035 is a pyrimidine carboxamide similar to Raltegravir, the first integrase inhibitor licensed for clinical use. BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity with IC50 of 15 nM. [1] However, several IN mutations, including V75I, Q148R, V151I, and G163R are found to confer resistance to HIV IN inhibitors. The binding of BMS-707035 and target DNA to IN are mutually exclusive events, as revealed by the fact that the inhibition of strand transfer catalysis by BMS-707035 is overcome by increasing amount of target DNA. The binding affinity of BMS-707035 to IN is also affected by the four terminal bases at the 5' end of the pre-processed U5 long terminal repeat (LTR). Gln148 of IN is crucial for the binding of BMS-707035 to IN. [1] The 3' terminus of the viral LTR, on the other hand, retards the rate of BMS-707035 association with IN, by regulating the kinetics of binding and dissociation. [2] |
Molecular Weight | 410.42 |
Formula | C17H19FN4O5S |
CAS No. | 729607-74-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 36 mg/mL (87.7 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-707035 729607-74-3 Microbiology/Virology Proteases/Proteasome HIV Protease HIV-1 integrase strand transfer HIV Human immunodeficiency virus antiviral phamacokinetics HIV Integrase BMS 707035 CYP inhibit strand transfer Inhibitor BMS707035 inhibitor